Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 5/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17873517 | 1.00 | GABRA1 (0.41) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL17873491 | 1.00 | GABRA1 (0.41) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL13681556 | 0.84 | GABRA1 (0.43) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL12311028 | 0.81 | GABRA1 (0.45) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL12311024 | 0.81 | GABRA1 (0.45) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL13681522 | 0.78 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL21230824 | 0.77 | ALOX5 (0.32) | ALDH1A1 | |
| SCHEMBL13681568 | 0.77 | GABRA1 (0.49) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL13681475 | 0.75 | GABRA1 (0.47) | GABRA1GABRG2GABRB3GABRB2GABRB1 | |
| SCHEMBL13681571 | 0.74 | PDE4A (0.49) | GABRA1GABRG2GABRB3GABRB2PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4302830-A2 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | Gilead Sciences, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-3960735-B1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230043136-A1 | Quinazoline Compounds | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2023-02-09 | — | — | US | disclosed |
| US-11304948-B2 | Quinazoline compounds | GILEAD SCIENCES, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3960735-A1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | Gilead Sciences, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| US-20200360383-A1 | Quinazoline Compounds | GILEAD SCIENCES, INC. | 2020-11-19 | — | — | US | disclosed |
| US-10548898-B2 | Quinazoline compounds | GILEAD SCIENCES INC. (US) | 2020-02-04 | — | — | US | disclosed |
| EP-3521282-A1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | Gilead Sciences, Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190134035-A1 | Quinazoline Compounds | GILEAD SCIENCES, INC. | 2019-05-09 | — | — | US | disclosed |
| US-10206926-B2 | Quinazoline compounds | GILEAD SCIENCES, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| EP-3237398-B1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | GILEAD SCIENCES INC (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20170354656-A1 | Quinazoline Compounds | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2017-12-14 | — | — | US | disclosed |
| EP-3237398-A1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | Gilead Sciences, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9730936-B2 | Quinazoline compounds | GILEAD SCIENCES, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160250215-A1 | QUINAZOLINE COMPOUNDS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2016-09-01 | — | — | US | disclosed |
| WO-2016105564-A1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | GILEAD SCIENCES, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11304948-B2 | Quinazoline compounds | TTBK1, TTBK2, MAPT | GABRA1 2037/4885GABRG2 3221/4885GABRB3 1861/4885 |
| US-20190134035-A1 | Quinazoline Compounds | TTBK1, TTBK2, MAPT | GABRA1 2037/4885GABRG2 3221/4885GABRB3 1861/4885 |
| US-10206926-B2 | Quinazoline compounds | TTBK1, TTBK2, MAPT | GABRA1 2037/4885GABRG2 3221/4885GABRB3 1861/4885 |
| US-20160250215-A1 | QUINAZOLINE COMPOUNDS | TTBK1, TTBK2, MAPT | GABRA1 2037/4885GABRG2 3221/4885GABRB3 1861/4885 |
| US-20200360383-A1 | Quinazoline Compounds | TTBK1, TTBK2, MAPT | GABRA1 2037/4885GABRG2 3221/4885GABRB3 1861/4885 |
| US-20230043136-A1 | Quinazoline Compounds | TTBK1, TTBK2, MAPT | GABRA1 2037/4885GABRG2 3221/4885GABRB3 1861/4885 |
| US-10548898-B2 | Quinazoline compounds | TTBK1, TTBK2, MAPT | GABRA1 2037/4885GABRG2 3221/4885GABRB3 1861/4885 |
| US-20170354656-A1 | Quinazoline Compounds | TTBK1, TTBK2, MAPT | GABRA1 2037/4885GABRG2 3221/4885GABRB3 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.